ESTRO 2024 - Abstract Book

S468

Clinical - Breast

ESTRO 2024

Figure 1. Dose distribution demonstrating 50% and 90% of prescribed dose for whole-breast in (A) helical and (B) TomoDirect plans using conventional clinical target volume, and (C) helical plan using implant sparing target volume for right-side breast, and same plans for left- side breast (D – F). The 50% isodose volume (blue area), 90% isodose volume (green area) and tumor-bed boost (orange area).

Conclusion:

Implant-sparing helical therapy reduced silicone doses but compromised target volume dose distribution, while conventional plans using H and TD techniques consistently demonstrated superior dosimetric outcomes. However, the unpredictable occurrence of capsular contracture during radiation therapy underscores the need for rigorous long-term clinical assessments to determine the most suitable approach for minimizing the potential risks and maximizing the benefits of implant sparing in breast cancer treatment.

Keywords: Breast Cancer, Radiotherapy, Breast Reconstruction